31 results
Thumbnail

D3.323 - SBK007: A Novel Oral H1 Antihistamine with Rapid Onset (30min): Preclinical Pharmacodynamics in Acute Urticaria

Thumbnail

D3.324 - Hereditary Angioedema Attack Frequency and Severity According to Individuals Taking Berotralstat for Long-Term Prophylaxis

Thumbnail

D3.325 - Immediate-type allergic reactions associated with thiuram mix sensitization in an adolescent with atopic dermatitis: a case report

Thumbnail

D3.328 - Paediatric Anaphylaxis: The Importance Of Recognition

Thumbnail

D3.329 - Real-world shelf-life of adrenaline auto-injectors (AAIs) at pharmacy dispensing: Insights from six countries

Thumbnail

D3.331 - Real-World Challenges in Pediatric Anaphylaxis: The Role of Epinephrine

Thumbnail

D3.332 - Patient Preferences for Nasal Adrenaline Spray versus Adrenaline Auto-Injectors in Anaphylaxis: A Multi-Country Discrete Choice Experiment

Thumbnail

D3.333 - Clinical Characteristics of Anaphylaxis in Infants and Toddlers

Thumbnail

D3.334 - Severe Early-Onset Atopy With Recurrent Anaphylaxis and Infections as Indicators of CADINS Disease

Thumbnail

D3.335 - Anaphylaxis After Eating Sushi - Emergent allergies with new food habits?

Thumbnail

D3.440 - Long-Term Efficacy and Safety of Donidalorsen for Hereditary Angioedema Among Patients in Europe: A Regional Analysis of the OASISplus Study

Thumbnail

D3.441 - Switching to Donidalorsen for Hereditary Angioedema: 1-Year Results From the Phase 3 OASISplus Study

Thumbnail

D3.444 - Efficacy and Safety of Donidalorsen for Patients With Hereditary Angioedema in Europe Who Switched From Prior Long-Term Prophylaxis: Results From the OASISplus Study

Thumbnail

D3.445 - Validation of a Novel Serum-Based Indirect Basophil Activation Test (iBAT) to Evaluate Efficacy of a Pivotal Phase III PQ Grass Immunotherapy Trial

Thumbnail

D3.437 - Impact of benralizumab on fatigue and health-related quality of life in patients with hypereosinophilic syndrome: findings from the NATRON phase 3 trial

Thumbnail

D3.438 - Clinical outcomes with navenibart according to baseline attack rate, body mass index, and age: results of the ALPHA-STAR trial

Thumbnail

D3.439 - Donidalorsen For The Treatment Of Hereditary Angioedema: 1-Year Results From The OASISplus Open-Label Extension Cohort

Thumbnail

D3.442 - Patient-Reported Outcomes With Long-Term Donidalorsen Treatment Among Patients In Europe With Hereditary Angioedema: 1-Year Interim Results From The OASISplus Open-Label Extension Cohort

Thumbnail

D3.443 - Patient-Reported Outcomes With Long-Term Donidalorsen Treatment Among Patients In Europe With Hereditary Angioedema: 1-Year Interim Results From The OASISplus Switch Cohort

Thumbnail

D3.446 - PROTECT Phase I/IIa Clinical Trial Demonstrated Strong Correlation Between Humoral Immune Response and Dose of VLP Peanut in Healthy Participants